Hannele Yki-Järvinen

The PNPLA3 I148M variant increases ketogenesis and decreases hepatic de novo lipogenesis and mitochondrial function in humans.

M. Orho-Melander, K. Petersen, S. Dufour, 2023, Cell metabolism.

Fatty Liver: A Novel Component of the Metabolic Syndrome

A. Kotronen, H. Yki-Järvinen, Hannele Yki-Järvinen, 2007, Arteriosclerosis, thrombosis, and vascular biology.

Marked difference in liver fat measured by histology vs. magnetic resonance-proton density fat fraction: A meta-analysis

T. Tukiainen, C. Sirlin, A. Juuti, 2023, JHEP reports : innovation in hepatology.

EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease

European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity, 2016, Obesity Facts.

IL32 downregulation lowers triglycerides and type I collagen in di-lineage human primary liver organoids

V. Kärjä, J. Pihlajamäki, V. Männistö, 2024, Cell Reports Medicine.

Surveillance of the liver in type 2 diabetes: important but unfeasible?

S. Qadri, Hannele Yki-Järvinen, 2024, Diabetologia.

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.

S. Zelber-Sagi, G. Frühbeck, V. W. Wong, 2024, Diabetologia.

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).

S. Zelber-Sagi, Vincent Wai‐Sun Wong, G. Frühbeck, 2024, Journal of hepatology.

NR1H4 rs35724 G>C Variant Modulates Liver Damage in Nonalcoholic Fatty Liver Disease

L. N. Valenti, J. Pihlajamäki, H. Yki-Järvinen, 2020, SSRN Electronic Journal.